 Cabaletta Bio, Inc. CABA, a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that the U.S. Food and Drug Administration FDA has granted Orphan Drug Designation for the Companys lead product candidate, DSG3-CAART, for the treatment of pemphigus vulgaris PV. DSG3-CAART is designed to target the cause of mucosal PV mPV, B cells that express pathogenic autoantibodies directed against the DSG3 protein, while preserving normal B cell immune function. 